[ CancerWeb Home
| Comments
| CancerWeb Report Index ]
The CancerWeb Report, What's New In Cancer
Prostate Cancer: December 1995
Last modified on:
Tuesday, April 20, 1999 12:03:10
Copyright © 1994-2008, Information Ventures, Inc.
PSA as a measure of suramin therapy -
PSA has been assuming an ever widening role in the management of
prostatic cancer. There is no question that elevated levels of
PSA can serve as an indicator of poor prognosis, and a warning of
advancing or recurrent disease. However, a number of recent
studies have extended use patterns to make the marker a surrogate
measure of response by the tumor to therapy. While this is a
logical step, a note of caution is sounded by an article in the
December, 1995 issue of the Journal of Clinical Oncology, from the
University of Maryland Cancer Center in Baltimore. The authors
who studied hormone-refractory disease found that although any
reduction in PSA may be associated with improved survival, PSA
was not in itself a reliable measure of the degree of response to
suramin therapy. Further evaluation is indicated.
Copyright (c) 1994-2008, Information Ventures, Inc.
Mail us at: Customer-Service@infoventures.com
http://infoventures.com